CERDULATINIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H27N7O3S
Molecular Weight	445.538
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCS(=O)(=O)N1CCN(CC1)C2=CC=C(NC3=NC=C(C(N)=O)C(NC4CC4)=N3)C=C2

InChI

InChIKey=BGLPECHZZQDNCD-UHFFFAOYSA-N

InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25)

HIDE SMILES / InChI

Molecular Formula	C20H27N7O3S
Molecular Weight	445.538
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.portola.com/clinical-development/cerdulatinib-dual-syk-jak-inhibitor/ | https://www.ncbi.nlm.nih.gov/pubmed/26575169
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25253883

Cerdulatinib is an oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor that uniquely inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies – the B-cell receptor pathway via Syk and key cytokine receptors via JAK Being developed to treat patients with hematologic cancers, specifically those who have relapsed or who have not responded to prior therapies. Cerdulatinib is in Phase 2 study evaluating the safety and efficacy of cerdulatinib in patients with relapsed/refractory B-cell malignancies who have failed multiple therapies.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Tyrosine-protein kinase TYK2 16 Target ID: CHEMBL3553 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25253883	Inhibitor 8297	0.5 nM [IC50]
Tyrosine-protein kinase SYK 21 Target ID: CHEMBL2599 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25253883	Inhibitor 8297	32.0 nM [IC50]
Tyrosine-protein kinase JAK3 27 Target ID: CHEMBL2148 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25253883	Inhibitor 8297	8.0 nM [IC50]
Tyrosine-protein kinase JAK1 38 Target ID: CHEMBL2835 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25253883	Inhibitor 8297	12.0 nM [IC50]
Tyrosine-protein kinase JAK2 55 Target ID: CHEMBL2971 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25253883	Inhibitor 8297	6.0 nM [IC50]
Serine/threonine-protein kinase MST1 2 Target ID: CHEMBL4598 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25253883	Inhibitor 8297	4.0 nM [IC50]
NUAK family SNF1-like kinase 1 4 Target ID: CHEMBL5784 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25253883	Inhibitor 8297	4.0 nM [IC50]
Mitogen-activated protein kinase kinase kinase 9 5 Target ID: CHEMBL2872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25253883	Inhibitor 8297	5.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Chronic lymphocytic leukemia 59 Sources: http://adisinsight.springer.com/drugs/800039086 https://clinicaltrials.gov/ct2/show/NCT01994382	Primary	Phase II 1132	Unknown Approved Use Unknown
Follicular lymphoma 3 Sources: http://adisinsight.springer.com/drugs/800039086 https://clinicaltrials.gov/ct2/show/NCT01994382	Primary	Phase II 1132	Unknown Approved Use Unknown
Non-Hodgkin's lymphoma 79 Sources: http://adisinsight.springer.com/drugs/800039086 https://clinicaltrials.gov/ct2/show/NCT01994382	Primary	Phase II 1132	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P008TVP	https://www.1pchem.com/search?query=1P008TVP
1PlusChem LLC	1P009ZFM	https://www.1pchem.com/search?query=1P009ZFM
AChemBlock	M15643	http://www.achemblock.com/catalogsearch/result/?q=M15643
ApexBio Technology	B8023	https://www.apexbt.com/catalogsearch/result/?q=B8023
AstaTech	C71670	http://astatechinc.com/CPSResult.php?CRNO=C71670
AstaTech	C72485	http://astatechinc.com/CPSResult.php?CRNO=C72485
Axon MedChem	2775	https://www.axonmedchem.com/product/2775
BLD Pharm	BD293312	http://www.bldpharm.com/search/Search.html?keyword=BD293312
BLD Pharm	BD764838	http://www.bldpharm.com/search/Search.html?keyword=BD764838
Chem Scene	CS-3329	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-3329
ChemShuttle	157204	https://www.chemshuttle.com/catalogsearch/result/?q=157204
Debye Scientific	DA-34986	https://www.debyesci.com/index.php?id=product&ext[cno]=DA-34986
Excenen	EX-A2143	http://www.excenen.com/searchresultlist.php?id=EX-A2143
KeyOrganics	AS-56368	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-56368
MedChem Express	HY-15999	https://www.medchemexpress.com/search.html?q=HY-15999&ft=&fa=&fp=
MolPort	MolPort-035-789-721	https://www.molport.com/shop/molecule-link/MolPort-035-789-721
MolPort	MolPort-042-676-155	https://www.molport.com/shop/molecule-link/MolPort-042-676-155
Molnova	M17872	https://www.molnova.com/en/serch-list.html?keywords=M17872
Molnova	M17977	https://www.molnova.com/en/serch-list.html?keywords=M17977
MuseChem	I000045	https://www.musechem.com/product/I000045.html
MuseChem	I000729	https://www.musechem.com/product/I000729.html
Ryan Scientific	IC261	https://ryansci.com/products?q=IC261&list_q=&search_type=exact
Selleck Chemicals	S7634	http://www.selleckchem.com/search.html?searchDTO.searchParam=S7634
ShangHai Biochempartner	BCP10681	http://www.biochempartner.com/search_BCP10681
ShangHai Biochempartner	BCP25893	http://www.biochempartner.com/search_BCP25893
TargetMol	T2487	https://www.targetmol.com/search?keyword=T2487
TargetMol	T6104	https://www.targetmol.com/search?keyword=T6104
eMolecules	50282202	https://orderbb.emolecules.com/search/#?query=50282202
eMolecules	50894592	https://orderbb.emolecules.com/search/#?query=50894592
eNovation Chemicals	D501928	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D501928&searchbtn.x=0&searchbtn.y=0
mcule	MCULE-5253065263	https://mcule.com/MCULE-5253065263/
mcule	MCULE-6000465165	https://mcule.com/MCULE-6000465165/

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Rat: in a rat collagen-induced arthritis model, Cerdulatinib (5 mg/kg p.o.) significantly improves inflammatory infiltrate within the synovium and the integrity of the articular cartilage.

Route of Administration: Oral

In Vitro Use Guide

In biochemical assays, cerdulatinib demonstrated inhibitory activity against 24 kinases with IC50’s < 200 nM. Cerdulatinib demonstrated sensitivity to cerdulatinib with IC50 at or below ~2 uM. ABC cell lines with relatively higher total and phosphorylated STAT3 displayed good sensitivity to the drug with IC50 ranging from 0.29 to 1.80 uM.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:35:25 GMT 2023` Edited by `admin` on `Sat Dec 16 01:35:25 GMT 2023`
Record UNII	D1LXQ45S1O
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CERDULATINIB

Official Name

English

5-PYRIMIDINECARBOXAMIDE, 4-(CYCLOPROPYLAMINO)-2-((4-(4-(ETHYLSULFONYL)-1-PIPERAZINYL)PHENYL)AMINO)-

Systematic Name

English

PRT-062070

Code

English

RVT-502

Code

English

cerdulatinib [INN]

Common Name

English

4-(CYCLOPROPYLAMINO)-2-((4-(4-(ETHANESULFONYL)PIPERAZIN-1-YL)PHENYL)AMINO)PYRIMIDINE-5-CARBOXAMIDE

Systematic Name

English

Cerdulatinib [WHO-DD]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

651118